Laurus Labs Limited (LAURUSLABS.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
6007
First IPO Date
December 19, 2016
| Name | Title | Pay | Year Born |
| Satyanarayana Chava | Chief Executive Officer & Whole Time Director | 248M | 1961 |
| Soumya Chava | Executive Director - Generics & Executive Director | 13.5M | 1986 |
| Krishna Chaitanya Chava | Executive Director of Synthesis & Executive Director | 22M | 1990 |
| Lakshmana Rao Venkata Chunduru | Executive Director of Quality & Executive Director | 45.6M | 1962 |
| Vantaram Venkata Ravi Kumar in Mgmt. | Chief Financial Officer & Whole-Time Director | 66M | 1965 |
| Chagarlamudi Sita Ramaiah | Executive Vice President of Finance | 0 | 1973 |
| Gogireddy Venkateswar Reddy | Vice President of Legal, Compliance Officer & Company Secretary | 0 | N/A |
| V. R. K. Suryadevara Srinivasa Rao | President of Manufacturing and Operations | 0 | 1968 |
| Narasimha Rao Chava | Executive Vice President of Human Resources | 0 | 1968 |
| Nurubasha Babchand | Senior Vice President of Generics | 0 | 1976 |
| Srinivasa Rao Suryadevara | Executive Vice President of Manufacturing | 0 | 1963 |
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.